tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

ARCT Stock Latest News

Positive Outlook on Arcturus Therapeutics Driven by Promising mRNA Advancements and Strategic Developments
RatingsPositive Outlook on Arcturus Therapeutics Driven by Promising mRNA Advancements and Strategic Developments
3d ago
ARCT
Arcturus Therapeutics Approves Key Proposals at Annual Meeting
PremiumCompany Announcements
Arcturus Therapeutics Approves Key Proposals at Annual Meeting
14d ago
8K
ARCT
Arcturus Therapeutics: Strategic Shift to Rare Disease Therapeutics and Strong Financial Position Drive Buy Rating
PremiumRatings
Arcturus Therapeutics: Strategic Shift to Rare Disease Therapeutics and Strong Financial Position Drive Buy Rating
15d ago
ARCT
Arcturus Therapeutics initiated with an Outperform at Scotiabank
PremiumThe Fly
Arcturus Therapeutics initiated with an Outperform at Scotiabank
23d ago
ARCT
Arcturus Therapeutics: Earnings Call Highlights Progress and Challenges
PremiumCompany Announcements
Arcturus Therapeutics: Earnings Call Highlights Progress and Challenges
1M ago
ARCT
Arcturus Therapeutics price target lowered to $45 from $50 at Wells Fargo
PremiumThe FlyArcturus Therapeutics price target lowered to $45 from $50 at Wells Fargo
1M ago
ARCT
Arcturus Therapeutics: Strategic Focus and Promising CF Program Drive Buy Rating
Premium
Ratings
Arcturus Therapeutics: Strategic Focus and Promising CF Program Drive Buy Rating
1M ago
ARCT
Promising Developments and Strategic Financial Management Drive Buy Rating for Arcturus Therapeutics
Premium
Ratings
Promising Developments and Strategic Financial Management Drive Buy Rating for Arcturus Therapeutics
1M ago
ARCT
Arcturus Therapeutics price target lowered to $66 from $68 at Canaccord
PremiumThe Fly
Arcturus Therapeutics price target lowered to $66 from $68 at Canaccord
1M ago
ARCT
Citi opens ’90-day Upside Catalyst Watch’ on Arcturus Therapeutics
PremiumThe Fly
Citi opens ’90-day Upside Catalyst Watch’ on Arcturus Therapeutics
1M ago
ARCT
Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside
PremiumRatings
Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside
1M ago
ARCT
Arcturus Therapeutics: Promising Vaccine Rollout and Cystic Fibrosis Treatment Drive Buy Rating
PremiumRatings
Arcturus Therapeutics: Promising Vaccine Rollout and Cystic Fibrosis Treatment Drive Buy Rating
1M ago
ARCT
Arcturus Therapeutics Reports Q1 2025 Financial Update
PremiumCompany AnnouncementsArcturus Therapeutics Reports Q1 2025 Financial Update
1M ago
ARCT
Arcturus Therapeutics reports Q1 EPS (52c), consensus ($1.10)
Premium
The Fly
Arcturus Therapeutics reports Q1 EPS (52c), consensus ($1.10)
1M ago
ARCT
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
ARCT
Arcturus Therapeutics: Promising Developments and Strategic Partnerships Drive Buy Rating
PremiumRatings
Arcturus Therapeutics: Promising Developments and Strategic Partnerships Drive Buy Rating
1M ago
ARCT
Arcturus Therapeutics: Promising Phase II Prospects for ARCT-032 in Cystic Fibrosis Amidst Regulatory Approvals
PremiumRatings
Arcturus Therapeutics: Promising Phase II Prospects for ARCT-032 in Cystic Fibrosis Amidst Regulatory Approvals
2M ago
ARCT
Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements
PremiumRatings
Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements
2M ago
ARCT
Arcturus Therapeutics granted fast track designation for ARCT-2304 from FDA
PremiumThe Fly
Arcturus Therapeutics granted fast track designation for ARCT-2304 from FDA
2M ago
ARCT
Arcturus Therapeutics price target lowered to $45 from $71 at Guggenheim
PremiumThe FlyArcturus Therapeutics price target lowered to $45 from $71 at Guggenheim
2M ago
ARCT
Optimistic Buy Rating for Arcturus Therapeutics Amid Promising Cystic Fibrosis Treatment Developments
Premium
Ratings
Optimistic Buy Rating for Arcturus Therapeutics Amid Promising Cystic Fibrosis Treatment Developments
3M ago
ARCT
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
3M ago
INO
ARCT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >